![Shaharyar Khan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shaharyar Khan
Technik-/Wissenschafts-/F&E-Leiter bei Rivus Pharmaceuticals, Inc.
Aktive Positionen von Shaharyar Khan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Rivus Pharmaceuticals, Inc.
![]() Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Direktor/Vorstandsmitglied | - | - |
Technik-/Wissenschafts-/F&E-Leiter | - | - |
Karriereverlauf von Shaharyar Khan
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Rivus Pharmaceuticals, Inc.
![]() Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Health Technology |
- Börse
- Insiders
- Shaharyar Khan
- Erfahrung